Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Seer Inc(SEER)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SEER
10/16/2026: SEER (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Seer Inc is a growth-stage company in the life sciences tools sector, focused on deep proteomic analysis through its proprietary nanoparticle-based Proteograph platform. Its primary strength lies in its ability to enable large-scale protein discovery, which addresses major gaps in traditional mass spectrometry workflows. The investment story centers on the potential for its technology to become a standard tool in biomarker and clinical research. Key risks include intense competition from established instrumentation giants, the high cost of adoption, and the challenge of scaling commercial operations. The stock is best suited for growth-oriented investors who can tolerate significant volatility, while investors should monitor adoption rates and strategic partnerships closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Seer fits the profile of a high-growth, technology-driven firm aiming to disrupt the proteomics research landscape. |
| Momentum investor | Mixed fit | Fit is conditional on positive market sentiment and sustained adoption signals for the Proteograph platform. |
| Value investor | Weak fit | The company is not currently profitable, making it unsuitable for traditional value-based investment strategies. |
| Dividend investor | Weak fit | Seer does not pay dividends and is focused entirely on capital reinvestment. |
| Low-risk investor | Weak fit | The high volatility and early-stage nature of the company represent significant risk for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As an early-stage life sciences company, the stock is subject to significant price swings based on research and commercial news. |
| Valuation risk | High | The stock's valuation is driven by future growth expectations, leaving little room for error in commercial execution. |
| Competition risk (Mass Spectrometry giants) | High | Seer must compete against entrenched incumbents with vast resources and established customer bases. |
| Business quality | Medium | While the technology is innovative, the business model is still proving its scalability in a crowded market. |
| Dividend income | Low / none | Investors should expect no income, as the company prioritizes growth and R&D. |
| Execution risk | Medium / high | The company's success depends on the consistent, widespread adoption of its Proteograph system by sophisticated researchers. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -69.28% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/16/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.41M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 262.6K shares | Beta 1.47 | 52 Weeks Range 1.55 - 2.41 | Updated Date 10/18/2026 |
52 Weeks Range 1.55 - 2.41 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Instrumentation and Consumables | The Proteograph Product Suite, including nanoparticle kits, hardware platforms, and data analysis software. | Revenue comes from selling advanced research equipment and the recurring reagents needed to run experiments. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value -29.96M | Price to Sales(TTM) 7.91 |
Enterprise Value -29.96M | Price to Sales(TTM) 7.91 | ||
Enterprise Value to Revenue 0.08 | Enterprise Value to EBITDA 1.72 | Shares Outstanding 55.37M | Shares Floating 40.46M |
Shares Outstanding 55.37M | Shares Floating 40.46M | ||
Percent Insiders 14.84 | Percent Institutions 49.22 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.